Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Tellurian (TELL) Jumps: Stock Rises 10.8%
Tellurian Inc. (TELL - Free Report) was a big mover last session, as the company saw its shares rise nearly 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $9.5 –$10.2 in the past one-month time frame, witnessed a sharp increase on Friday.
The company has seen two its Zacks Consensus Estimate for the current quarter moving lower in the last one month, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
Tellurian currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.
Tellurian Inc. Price and Consensus
Tellurian Inc. Price and Consensus | Tellurian Inc. Quote
A better-ranked stock in the Oil and Gas - Refining and Marketing industry is Delek US Holdings, Inc. (DK - Free Report) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is TELL going up? Or down? Predict to see what others think: Up or Down
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>